ABSTRACT

Objective: Buccal patch is a non-dissolving thin matrix modified release dosage form which was developed to administer into the unconscious and less co-operative patients.

Methods: The mucoadhesive buccal patches of hydrochlorothiazide (HCZ) and atenolol (ATN) were prepared by solvent casting technique using various concentrations of sodium alginate, hydroxy propyl methyl cellulose, carbopol 934P and sodium carboxy methyl cellulose polymer and polyvinyl alcohol as a backing layer. The formulated patches were evaluated for their physicochemical parameters like thickness, weight variation, surface pH, content uniformity, folding endurance, swelling percentage studies and tensile strength, in vitro and ex vivo drug permeation.

Results: The infra-red (IR) spectra showed no interaction between drug and polymer. Physicochemical characteristics of all the samples were found to be satisfactory and well within the range. Swelling of the films were increased with the increasing content of the polymers and it was found that swelling front erosion was comparably slower in the formulations with the carbopol 934 and HPMC. This is probably due to their marked viscous properties and therefore formulation provided sustained release of the drug. The percentage drug content of all the formulations were found to be in the range of 97-99 %. Among the patches, FC (Carbopol 934 and HPMC) patches were considered satisfactory for maintaining the in vitro residence in the oral cavity for almost 8h. Formulations FD (with CP and NaCMC) and FC showed high tensile strength and % E/B which is an indication of the strength and elasticity of the patch. The films were exhibited sustained release for more than 6 h which was confirmed by the in vitro release data and kinetic data reveals the combination of diffusion and erosion mechanism. The best mucoadhesive performance and matrix controlled release was exhibited by the formulation FC.

Conclusion: The formulation of HCZ and ATN mucoadhesive buccal patch was found to be satisfactory and reasonable.

Keywords: Buccal mucoa, Solvent casting method, HPMC, Hydrochlorothiazide, Atenolol, Mucoadhesive buccal patches

INTRODUCTION

Mucoadhesive polymers are synthetic or natural macromolecules which are capable of attaching to mucosal surfaces. Mucoadhesive drug delivery system has been accepted as a promising strategy to prolong the residence time and to improve the specific localization of drug on various membranes. Among the various routes of drug delivery, the oral route is perhaps the most preferred to the patient and the clinician alike [1]. However, peroral administration of drugs has disadvantages such as hepatic first pass metabolism and enzymatic degradation within the GI tract, that prohibit oral administration of certain classes of drugs especially peptides and proteins. Consequently, other absorptive mucosal are considered as potential sites for drug administration. Transmucosal routes of drug delivery (i.e., the mucosal linings of the nasal, rectal, vaginal, ocular, and oral cavity) offer distinct advantages over per oral administration for systemic drug delivery. These advantages include a possible bypass of first pass effect, avoidance of pre-systemic elimination within the GI tract, and, also provides a better enzymatic flora for drug absorption. Most of the antihypertensive formulations are available in the market are in the form of tablets. Of them do present varying degree of disadvantages in terms of efficacy, absorption and bioavailability and sometimes show undesirable side effects due to fluctuating plasma drug level [2, 3].

The effort was made here to formulate the combination of HCZ and ATN as a buccal patch to provide sustained release of drug and to bypass hepatic first-pass metabolism during the treatment of hypertension. HCZ has a half-life of 5-6 h, bioavailability is around 70 % and classified as BCS class 4 systems. It is mainly eliminated by the kidney and its protein binding is approximately 70 %. On the other hand, ATN has a half-life of 6-7 h. Duration of action is found to be 24 h (once daily dosing). Absorption of the drug is found to be absorbed slowly and incompletely from GI tract (oral) and peak plasma concentration is achieved after 7 h. The bioavailability of ATN is around 25 %. The combination of ATN and HCZ is available in the market as tablets, for the treatment of hypertension.

Hence, buccal patches containing the combination of HCZ and ATN was designed and evaluated.

MATERIALS AND METHODS

Materials

Hydrochlorothiazide and Atenolol were procured by Yarrow Chem. Pvt. Ltd. polyvinyl alcohol, polyvinylpyrrolidone, ethyl cellulose, hydroxy propyl methyl cellulose, sodium alginate and carbopol 934 were procured by CDH laboratory Reagent, New Delhi. All other chemicals and reagents were of analytical grade.

Methods

Preformulation study

FTIR studies

Compatibility of HCZ and ATN with the excipients was confirmed by FTIR studies. The pure drugs, HCZ and ATN with the polymers in the ratio of 1:1 were taken and the potassium bromide disc (pellet) method was employed to conduct the study. After collecting an interferogram of a sample containing pure HCZ and ATN and drugs with the polymers, FTIR spectroscopic analysis was performed on the interferogram to obtain the spectrum.

Method of preparation

A series of buccal patches composed of different proportions and combinations of sodium alginate (SA) (100 to 300 mg), hydroxypropyl methyl cellulose (HPMC) (200 to 400 mg), carbopol
Evaluation of buccal patches

Uniformity of weight
Ten patches of 1 cm² were weighed individually and average of those patches measured [5].

Patch thickness
The thickness of each patch was measured using screw gauge at five different positions of the patch and the average was calculated.

Folding endurance
Folding endurance of the patches was determined by repeatedly folding one patch at the same place till it broke or folded up to 300 times manually, which was considered satisfactory to reveal good patch properties. The number of times of patch could be folded at the same place without breaking gave the value of the folding endurance. This test was done on five patches [6].

Surface pH of the buccal patches
The surface pH of the patches was determined to investigate the possibility of any side effects due to change in pH in vivo, since an acidic or alkaline pH may cause irritation to the buccal mucosa. The patch to be tested was placed in petri dish and was moistened with 0.5 ml of distilled water and kept for 30s. The pH was noted after bringing an electrode of pH meter in contact with the surface of the formulation and allowing equilibrating for 1 min [6].

Measurement of bioadhesive strength
Bioadhesive strength refers to mechanical strength of the system. Bioadhesive strength test was conducted to check the residence time of the patch at the site of application. The tensile strength required to detach the bioadhesive patch from the mucosal surface was reported as a parameter of the bioadhesive performance. In the present work, a specially designed or fabricated assembly based on published literature was used. Porcine cheek pouch was used as a model surface for bioadhesion testing. After the cheek pouch was excised and trimmed evenly, it was then washed in simulated salivary fluid, and then used immediately [7].

Swelling index
The swelling index procedure was used to determine the general swelling characteristics of patch. A drug-loaded patch of 1×1 cm² was weighed on a pre-weighed cover slip. It was kept in a petridish and 50 ml of phosphate buffer, pH 6.8 was added. After every five min, the cover slip was removed and weighed up to 30 min. The table below gives the weight of the patch at time zero.

\[
\text{Swelling index} = \frac{W_t - W_0}{W_0}
\]

where, \(W_t\) is weight of the patch at time \(t\) and \(W_0\) is weight of the patch at time zero.

Drug content
Prepared buccal patch was dissolved in 100 ml of phosphate buffer solution (PBS) of pH 6.8 using a magnetic stirrer for 12 h and then sonicated for 30 min designed to contain each 200 mg of HCZ and ATN. After filtration to remove insoluble residue, 1 ml of filtrate was sonicated for 30 min designed to contain each 200 mg of HCZ and ATN. After filtration to remove insoluble residue, 1 ml of filtrate was sonicated for 30 min designed to contain each 200 mg of HCZ and ATN. After filtration to remove insoluble residue, 1 ml of filtrate was sonicated for 30 min designed to contain each 200 mg of HCZ and ATN. After filtration to remove insoluble residue, 1 ml of filtrate was sonicated for 30 min designed to contain each 200 mg of HCZ and ATN. After filtration to remove insoluble residue, 1 ml of filtrate was sonicated for 30 min designed to contain each 200 mg of HCZ and ATN. After filtration to remove insoluble residue, 1 ml of filtrate was sonicated for 30 min designed to contain each 200 mg of HCZ and ATN. After filtration to remove insoluble residue, 1 ml of filtrate was sonicated for 30 min designed to contain each 200 mg of HCZ and ATN. After filtration to remove insoluble residue, 1 ml of filtrate was sonicated for 30 min designed to contain each 200 mg of HCZ and ATN. After filtration to remove insoluble residue, 1 ml of filtrate was.
Patches of dimension 1×1 cm solution (PBS) of pH 6.8 was used as medium for diffusion study. Diffusion cell across cellophane membrane. Phosphate buffer respectively for HCZ and ATN [11, 12]. Using UV-Visible spectrophotometer 235.5 and 264.5 nm with suitable dilution, samples were measured for absorbance at predetermined interval and was replaced with fresh PBS of pH 6.8. The amount of HCZ and ATN released into the receptor medium was quantified by using UV-Visible Spectrophotometer at 235.5 and 264.5 nm respectively against a blank [13, 14].

In vitro release study
A patch of 2×2 cm size was cut and attached to a glass slide with a few drops of phosphate buffer (pH 6.8). This slide was kept at an angle of 45 °C in a 250 ml beaker containing 100 ml of phosphate buffer (pH 6.8) solution. The beaker was kept in circulating water bath in which the temperature was maintained at 37 °C. A non-agitated system was selected to eliminate any effect of turbulence on the release rate. Samples were withdrawn periodically after removing the slide from the beaker. The solution was stirred with a glass rod and 5 ml of sample was withdrawn using a graduated pipette, whose tip was attached to a tube with glass wool (as a filter). The slide was quickly reintroduced into the beaker. 5 ml of the buffer was replaced immediately and the beaker was kept covered with a petridish to prevent evaporation of the fluid. The samples were taken after every 10 min up to 90 min and analysed for drug contents.

The withdrawn samples were analyzed spectrophotometrically at 235.5 nm and 264.5 nm for HCZ and ATN respectively for HCZ and ATN [11, 12]. With suitable dilution, samples were measured for absorbance using UV-Visible spectrophotometer 235.5 nm and 264.5 nm for HCZ and ATN respectively by using Shimadzu double beam ultra violet-visible spectrophotometer (UV-1700, Shimadzu Corporation, Tokyo, Japan). The release studies were conducted for three times and average was determined for HCZ and ATN [9, 10].

In vitro diffusion study
In vitro diffusion study was performed by using modified Franz diffusion cell across cellophane membrane. Phosphate buffer solution (PBS) of pH 6.8 was used as medium for diffusion study. Patches of dimension 1×1 cm were placed on the membrane, which was placed between donor and receptor compartment of Franz diffusion cell. Cellophane membrane was brought in contact with PBS of pH 6.8 filled in receptor compartment. Temperature was maintained at 37 °C with stirring at 50 rpm using magnetic bead stirrer. 1 ml of sample was withdrawn from receptor compartment at predetermined interval and was replaced with fresh PBS of pH 6.8. With suitable dilution, samples were measured for absorbance using UV-Visible spectrophotometer 235.5 and 264.5 nm respectively for HCZ and ATN [11, 12].

Ex vivo permeability study
The extent and rate of mucosal permeation of HCZ and ATN through the porcine buccal mucosa were carried out using Franz diffusion cell. The effective diffusion area was 1.8 cm². The receptor compartment (40 ml) was filled with PBS, pH 6.8, and its temperature was maintained at 37±0.5 °C. 50 rpm stirring speed was applied using a magnetic stirrer to simulate buccal cavity environment. The patch of 1×1 cm was applied under occlusion on the buccal mucosal surface of the goat fitted between the donor and receptor compartments of the diffusion cell. 5 ml of the sample from receptor medium was withdrawn at regular intervals and replaced immediately with an equal volume of PBS, pH 6.8. The amount of HCZ and ATN released into the receptor medium was quantified by using UV-Visible Spectrophotometer at 235.5 and 264.5 nm respectively against a blank [13, 14].

Kinetic analysis
To analyse the mechanism of the drug release rate kinetics of the dosage form, the data obtained were fitted into % cumulative drug release (CDR) vs time for Zero order kinetics, Log % CDR remaining vs time for First order kinetics, % CDR vs Square root of time for Higuchi model and Log % CDR vs Logt for Korsmeyer model were plotted to obtain R² values [15].

Stability study
Stability testing of drug products begins as a part of drug discovery and ends with the demise of the compound or commercial product. Food and Drug Administration (FDA) and International conference of Harmonization (ICH) specifies the guidelines for stability testing of new drug products, as a technical requirement for the registration of pharmaceuticals for human use. The ICH Tripartite Guidelines have established that long term stability testing should be done at 25 °C/60 % (Relative Humidity) RH; stress testing should be done at 40 °C/75 % RH for 6 mo. If significant change occurs at these stress conditions, then the formulation should be tested at an intermediate condition i.e. 30 °C/75 % RH. In the present study stability studies were carried out at two different temperatures i.e., refrigeration temperature (2±8 °C) and room temperature (25±30 °C) [14, 15].

RESULTS AND DISCUSSION
Compatibility studies
IR studies were carried out for pure drugs and excipients which were used in formulations to determine the interaction between drug and polymers. The IR spectra are given in the fig. 1a, b,c and d. The spectral values for the drugs were compared with reference standard sample spectra. The IR spectrum of the HCZ showed the characteristic peaks at 3362.04 cm⁻¹ (NH stretching group), 1650 cm⁻¹ (C=C group), 3200-3550 cm⁻¹ (-OH group). The IR spectrum of the ATN showed the characteristic peaks at 2916-2936 cm⁻¹ (CH group), 2850 cm⁻¹ (CH₂ group), 1640-1610 cm⁻¹ (C=C group), 3200-3550 cm⁻¹ (-OH group). The spectra of formulations showed presence of peaks in the region of characteristic peaks of drugs confirmed the absence of interaction between the drugs and excipients used in the formulation.

In vitro release study
Percentage elongation = \dfrac{\text{increase in length}}{\text{original length}} \times 100

\text{Ex vivo permeability study}

\text{Stability study}

\text{Compatibility studies}

\text{RESULTS AND DISCUSSION}

\text{Fig. 1a: FTIR spectra of pure HCZ}
Physico-chemical evaluation of prepared buccal patches

All formulated patches were found to be smooth in texture and transparent. The individual weight of 3 formulations of each type were determined and the average weight was calculated. It was observed that the weight of the patches in each formulation was found to be uniform. The thickness of the patches of each formulation was determined using micrometer screw gauge. It was observed that the thickness of all patch samples were found to be uniform in each formulation. The patches with increased polymer content showed a marginal increase in thickness. The folding endurance was determined as per the procedure mentioned in the methodology. It was found that all the formulations showed good folding endurance greater than 300. The surface pH of the patches was also determined and observed that the surface pH of each patch was found between 6.15 to 6.66 and which means that they may have less potential to irritate the buccal mucosa, as a result patches will be compatible to mucosa. The percentage drug content of all formulations was found to be in the range of 97-99%. Among the formulations prepared, it was observed that FC takes longer time to disintegrate since it contains Carbopol 934 and HPMC which is highly viscous at increased concentration [16, 17]. The results for all formulations and the average of 3 determinations are given in table 2.
patch adhesion and consequently the drug release from the patch. The hydration and swelling also affects the strength due to disentanglement at the polymer tissue interface. The point where over hydration leads to an abrupt drop in adhesive surface. The adhesion increases with the degree of hydration until a necessary to initiate intimate contact of the patch with the mucosal surface. Measurement of swelling index

The hydration and swelling behavior of the polymer was reported to be crucial for its bio adhesive character because the former is necessary to initiate intimate contact of the patch with the mucosal surface. The adhesion increases with the degree of hydration until a point where over hydration leads to an abrupt drop in adhesive strength due to disentanglement at the polymer tissue interface. The rate and the extent of patch hydration and swelling also affects the patch adhesion and consequently the drug release from the patch. Studies have shown that excessive hydration can lead to weakening of the adhesive bond due to dilution of functional groups responsible for the adhesive interaction between the bio adhesive patch and mucosa. It was found that the increase in swelling of patches formulated with Carbopol 934 and HPMC was more compared to other formulations. This result may be attributed to complete penetration of solvent and high viscosity of the carbopol 934. The obtained results showed that the swelling front erosion was comparably slower in formulation batch with Carbopol 934 and HPMC due to their marked viscosity properties. Hence the formulation provides sustained release of drug. The poor solubility of SA limits the swelling of the patch [17].

**Table 2: Results of physic-chemical parameters**

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Weight (mg)</th>
<th>Thickness (mm)</th>
<th>Surface pH</th>
<th>Folding endurance</th>
<th>Drug content (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FA 1</td>
<td>39±0.04</td>
<td>0.54±0.02</td>
<td>6.3</td>
<td>326</td>
<td>30±0.10</td>
</tr>
<tr>
<td>2</td>
<td>38±0.03</td>
<td>0.56±0.03</td>
<td>6.2</td>
<td>314</td>
<td>35±0.12</td>
</tr>
<tr>
<td>3</td>
<td>40±0.04</td>
<td>0.57±0.02</td>
<td>6.3</td>
<td>339</td>
<td>40±0.13</td>
</tr>
<tr>
<td>FB 1</td>
<td>45±0.02</td>
<td>0.53±0.04</td>
<td>6.1</td>
<td>348</td>
<td>40±0.04</td>
</tr>
<tr>
<td>2</td>
<td>46±0.05</td>
<td>0.58±0.05</td>
<td>6.3</td>
<td>335</td>
<td>45±0.06</td>
</tr>
<tr>
<td>3</td>
<td>48±0.06</td>
<td>0.54±0.05</td>
<td>6.3</td>
<td>335</td>
<td>45±0.06</td>
</tr>
<tr>
<td>FC 1</td>
<td>49±0.04</td>
<td>0.56±0.03</td>
<td>6.6</td>
<td>333</td>
<td>50±0.07</td>
</tr>
<tr>
<td>2</td>
<td>47±0.06</td>
<td>0.56±0.03</td>
<td>6.3</td>
<td>350</td>
<td>60±0.07</td>
</tr>
<tr>
<td>3</td>
<td>48±0.04</td>
<td>0.51±0.04</td>
<td>6.3</td>
<td>315</td>
<td>35±0.08</td>
</tr>
<tr>
<td>FD 1</td>
<td>49±0.03</td>
<td>0.54±0.03</td>
<td>6.2</td>
<td>310</td>
<td>30±0.08</td>
</tr>
<tr>
<td>2</td>
<td>48±0.04</td>
<td>0.51±0.04</td>
<td>6.1</td>
<td>315</td>
<td>35±0.08</td>
</tr>
<tr>
<td>3</td>
<td>44±0.02</td>
<td>0.59±0.02</td>
<td>6.3</td>
<td>325</td>
<td>45±0.12</td>
</tr>
</tbody>
</table>

*n=3, SD-standard deviation, F-formulation

**Measurement of swelling index**

The hydration and swelling behavior of the polymer was reported to be crucial for its bio adhesive character because the former is necessary to initiate intimate contact of the patch with the mucosal surface. The adhesion increases with the degree of hydration until a point where over hydration leads to an abrupt drop in adhesive strength due to disentanglement at the polymer tissue interface. The rate and the extent of patch hydration and swelling also affects the patch adhesion and consequently the drug release from the patch. Studies have shown that excessive hydration can lead to weakening of the adhesive bond due to dilution of functional groups responsible for the adhesive interaction between the bio adhesive patch and mucosa. It was found that the increase in swelling of patches formulated with Carbopol 934 and HPMC was more compared to other formulations. This result may be attributed to complete penetration of solvent and high viscosity of the carbopol 934. The obtained results showed that the swelling front erosion was comparably slower in formulation batch with Carbopol 934 and HPMC due to their marked viscosity properties. Hence the formulation provides sustained release of drug. The poor solubility of SA limits the swelling of the patch [17].

**Bioadhesive strength**

*In vitro* mucoadhesive strength was determined on the modified balance to measure the force of adhesion (N) required to detach the tablet. From the overall study it was concluded that the mucoadhesive strength of polymers depend on their structure and other physicochemical properties. As the mucoadhesive polymer mixture concentration increased, the mucoadhesive strength and force of adhesion increased. Very strong mucoadhesion could damage the epithelial lining of the buccal mucosa. Among all the formulations FC (Carbopol 934 and HPMC) has higher mucoadhesive strength and higher the force required to detach from mucosa. Therefore FC patches can be considered satisfactory for maintaining them in the oral cavity for 8h. Among FA and FD maximum bioadhesion was observed for SA patches [18, 19].

**Tensile strength (TS) and percentage elongation (E/B)**

The TS gives an indication of the strength and elasticity of the patch. A weak and soft polymer is characterized by a low TS and E/B, a hard and brittle polymer shows a moderate TS and low E/B, a soft and tough polymer is characterized by a moderate TS and high E/B whereas a hard and tough polymer shows a high TS and E/B. The results showed that, among the formulation FA to FD, TS and E/B increased with the increase in the percentage of polymers. Formulations FD (with CP and NaCMC) and FC (Carbopol 934 and HPMC) showed high Tensile strength and % E/B than FA (with SA and HPMC) and FB (HPMC and NaCMC) which indicated that FC and FD gives good tensile strength to buccal patches which are tough and strong enough for use compared to FA and FB. In case of formulations FA and FD, FA (SA and HPMC) at higher concentration showed TS and E/B greater compared to formulation FD (CP and NaCMC), indicated that the inclusion of CP decreased the tensile strength. This indicates that the presence of water soluble polymers tend to make the polymer softer and less tough and therefore poor TS and E/B [19] (table 3).

**In vitro release studies**

Amongst the formulations FC2 containing carbopol 934 and HPMC (2:3) released the drug in sustained form i.e. 95 % at 8 h since carbopol 934 at higher concentration created a high viscosity gel barrier for drug diffusion. Increased concentrations of NaCMC resulted faster drug release. This result was attributed to water soluble polymer NaCMC, results in increased wettability and penetration of water into the patch matrices and hence increased diffusion of the drug [20] (fig. 3 and 4).
Table 3: Tensile strength and % elongation of different formulations

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Tensile strength (Kg/mm²)</th>
<th>% Elongation</th>
</tr>
</thead>
<tbody>
<tr>
<td>FA 1</td>
<td>0.89±0.01</td>
<td>37.5±0.03</td>
</tr>
<tr>
<td>FA 2</td>
<td>0.79±0.02</td>
<td>39.1±0.04</td>
</tr>
<tr>
<td>FA 3</td>
<td>0.85±0.03</td>
<td>55.0±0.05</td>
</tr>
<tr>
<td>FB 1</td>
<td>0.65±0.02</td>
<td>19.0±0.02</td>
</tr>
<tr>
<td>FB 2</td>
<td>0.60±0.02</td>
<td>20.0±0.01</td>
</tr>
<tr>
<td>FB 3</td>
<td>0.62±0.01</td>
<td>25.7±0.03</td>
</tr>
<tr>
<td>FC 1</td>
<td>1.15±0.03</td>
<td>90.1±0.01</td>
</tr>
<tr>
<td>FC 2</td>
<td>1.17±0.03</td>
<td>89.7±0.04</td>
</tr>
<tr>
<td>FC 3</td>
<td>1.19±0.02</td>
<td>85.2±0.05</td>
</tr>
<tr>
<td>FD 1</td>
<td>0.95±0.01</td>
<td>57.0±0.01</td>
</tr>
<tr>
<td>FD 2</td>
<td>0.98±0.01</td>
<td>59.0±0.01</td>
</tr>
<tr>
<td>FD 3</td>
<td>0.94±0.02</td>
<td>60.0±0.04</td>
</tr>
</tbody>
</table>

n=3, SD-standard deviation, F-formulation, %-percentage

Fig. 3: *In vitro* drug release of HCZ, (Results are expressed as as mean±standard deviation; n=3)

Fig. 4: *In vitro* drug release of ATN, (Results are expressed as as mean±standard deviation; n=3)

Fig. 5: *In vitro* diffusion of HCZ, (Results are expressed as as mean±standard deviation; n=3)

Fig. 6: *In vitro* diffusion of ATN, (Results are expressed as as mean±standard deviation; n=3)

Fig. 7: *In vitro* drug permeation of HCZ, (Results are expressed as as mean±standard deviation; n=3)

Fig. 8: *In vitro* drug permeation of ATN, (Results are expressed as as mean±standard deviation; n=3)
In vitro diffusion studies

It was found that in FC 2 formulation containing carbopol 934 and HPMC (2:3) was found to be comparable with the in vitro diffusion study data and hence indicated a good diffusion coefficient which is essential for all such drugs which are formulated for the purpose of sustained formulations. Hence FC 2 was found to be better amongst the formulation [21]. This may be attributed due to increasing concentration of polymers [21] (fig. 5 and 6).

Ex vivo permeation studies

It was observed that, as the polymer content increased, the % drug permeation decreased. The formulation containing Carbopol 934 and HPMC showed better permeation compared to all other formulations. It was found that the results obtained in ex vivo study indicated that drug has the better ability to cross the buccal barrier at a faster rate and hence the delivery system has the potential of overcoming the drawbacks associated with presently available tablet formulations in the market (fig. 7 and 8).

Kinetic analysis

In order to determine the release mechanism that provides the best description to the pattern of drug release, the in vitro release data were fitted to Zero order, First order, and Higuchi model. The release data were also kinetically analysed using the Korsmeyer-Peppas model. The data were processed for regression analysis using MS–EXCEL statistical function [22] (table 4).

Table 4: Kinetic release of different formulations

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Zero order R²</th>
<th>First order R²</th>
<th>Higuchi model R²</th>
<th>Korsmeyer peppas model</th>
<th>N²</th>
</tr>
</thead>
<tbody>
<tr>
<td>FA 1</td>
<td>0.9736</td>
<td>0.9963</td>
<td>0.7122</td>
<td>0.9656</td>
<td>0.4535</td>
</tr>
<tr>
<td>2</td>
<td>0.9798</td>
<td>0.9950</td>
<td>0.6968</td>
<td>0.9776</td>
<td>0.4578</td>
</tr>
<tr>
<td>3</td>
<td>0.9798</td>
<td>0.9866</td>
<td>0.6977</td>
<td>0.9780</td>
<td>0.4598</td>
</tr>
<tr>
<td>FB 1</td>
<td>0.9657</td>
<td>0.9933</td>
<td>0.6736</td>
<td>0.9638</td>
<td>0.4637</td>
</tr>
<tr>
<td>2</td>
<td>0.9783</td>
<td>0.9960</td>
<td>0.6923</td>
<td>0.9778</td>
<td>0.4789</td>
</tr>
<tr>
<td>3</td>
<td>0.9702</td>
<td>0.9897</td>
<td>0.6886</td>
<td>0.9734</td>
<td>0.4739</td>
</tr>
<tr>
<td>PC 1</td>
<td>0.9766</td>
<td>0.9933</td>
<td>0.7210</td>
<td>0.9938</td>
<td>0.4761</td>
</tr>
<tr>
<td>2</td>
<td>0.9826</td>
<td>0.9976</td>
<td>0.6825</td>
<td>0.9866</td>
<td>0.4839</td>
</tr>
<tr>
<td>3</td>
<td>0.9819</td>
<td>0.9878</td>
<td>0.6999</td>
<td>0.9880</td>
<td>0.4817</td>
</tr>
<tr>
<td>FD 1</td>
<td>0.9656</td>
<td>0.9945</td>
<td>0.6856</td>
<td>0.9333</td>
<td>0.4839</td>
</tr>
<tr>
<td>2</td>
<td>0.9742</td>
<td>0.9913</td>
<td>0.6890</td>
<td>0.9413</td>
<td>0.4981</td>
</tr>
<tr>
<td>3</td>
<td>0.9668</td>
<td>0.9955</td>
<td>0.6843</td>
<td>0.9766</td>
<td>0.4937</td>
</tr>
</tbody>
</table>

F-formulation

By using Korsmeyer-Peppas model, if n = 0.45 it is Case-1 or Fickian diffusion, 0.45<n<0.89 is for anomalous behavior or non fickian transport, n = 0.89 for Case 11 transport, and n>0.89 for Super Case 11 transport. Fickian release usually occurs by molecular diffusion and state transition in hydrophilic glassy polymers, which swell in water or biological fluids. This term also includes polymer disentanglement and erosion. In the present investigation, the release from the polymers followed anomalous behavior or non-fickian transport. As a result the combination of diffusion and erosion was the mechanism followed by the formulations as the ‘n’ values ranged from 0.4533 to 0.4937 as per Korsmeyer-Peppas model, which in turn justified suitability of polymers for the preparation of buccal patches [22]

Stability studies

Stability testing was carried out for all the formulations for a period of eight weeks. All the formulations were evaluated with respect to physical appearance, drug content, surface pH, swelling index and in vitro drug release. The results of stability studies of HCZ and ATN buccal patches showed no significant change with respect to physical appearance, drug content, surface pH, swelling index and in vitro drug release at the end of eight weeks when stored in refrigeration temperature (2±8 °C) and room temperature (25±30 °C). Ageing did not alter the drug release profiles of any of the patches significantly till the end of the storage period. Buccal patches were found to be physically and chemically stable.

CONCLUSION

Sustained release patch may open a new horizon in buccal drug delivery system. In the present investigation, an attempt was made to improve the systemic bioavailability, avoidance of pre-systemic elimination within the GI tract and optimize therapeutic efficacy of the selected drugs by designing carefully mucoadhesive buccal patches for control release of HCZ and ATN. HCZ and ATN are available in combination in conventional tablet form in a market and are effective in the combination for the treatment of hypertension. Hence this drug combination will benefit from formulation into mucoadhesive buccal patches by avoiding first pass metabolism and therefore improvement in bioavailability and also improves patient compliance by reducing dosing frequency.

ACKNOWLEDGEMENT

The authors wish to acknowledge the Shree Devi college of Pharmacy, Mangalore, India for providing necessary facilities and financial support to carry out this project. The authors are also thankful to Bhagwant University for accepting the research project. The authors are thankful to Department of Pharmacuetics, NGSM Institute of Pharmaceutical Sciences, Nirta University, Mangalore for the logistic support and guidance.

AUTHORS CONTRIBUTIONS

All authors have contributed equally

CONFLICT OF INTERESTS

Declared none

REFERENCES


